Valuation: Waverley Pharma Inc.

Market Cap 540K 378K 338K 314K 286K 36.63M 542K 3.78M 1.48M 18.67M 1.42M 1.39M 59.93M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 3.94M 2.76M 2.47M 2.29M 2.09M 267M 3.96M 27.61M 10.82M 136M 10.37M 10.14M 437M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 month-33.33%
3 months-60.00%
Current year-50.00%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.12
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 01/02/2020
Director of Finance/CFO - 01/01/2020
Director TitleAgeSince
Chairman 79 14/12/2016
Director/Board Member 54 14/12/2016
Director/Board Member - 22/11/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/8/26 Option

Chairman

-10,000,000 18.5185%
24/6/24 Other

Director

0 0%
18/8/21 Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-60.00%-71.43% 378K
-2.59%-5.70%+50.69%+79.01% 70.61B
+0.55%-9.85%+4.99%+52.46% 51.01B
+0.30%-0.14%+8.42%+32.99% 48.1B
+0.51%-1.86%+28.15%+32.14% 42.78B
+0.65%-8.09%+291.53%+688.72% 40.67B
-0.17%-2.46%+7.86%+100.16% 40.3B
-2.13%-1.64%+8.63%+46.15% 30.59B
-2.23%-4.96%+46.01%+6.04% 28.16B
-0.12%-0.76%-5.28%-11.02% 24.36B
Average -0.52%-2.39%+38.10%+95.52% 37.66B
Weighted average by Cap. -0.61%-2.94%+50.58%+118.38%

Financials

2024 2025
Net sales 475K 333K 298K 277K 252K 32.24M 477K 3.33M 1.31M 16.44M 1.25M 1.22M 52.75M 1.35M 946K 845K 786K 715K 91.54M 1.36M 9.46M 3.71M 46.67M 3.55M 3.47M 150M
Net income -947K -664K -593K -551K -502K -64.24M -951K -6.64M -2.6M -32.75M -2.49M -2.44M -105M -499K -350K -312K -291K -264K -33.86M -501K -3.5M -1.37M -17.26M -1.31M -1.29M -55.4M
Net Debt 2.83M 1.98M 1.77M 1.65M 1.5M 192M 2.84M 19.84M 7.77M 97.88M 7.45M 7.29M 314M 3.4M 2.38M 2.13M 1.98M 1.8M 231M 3.41M 23.82M 9.33M 118M 8.95M 8.75M 377M
Projected Income Statement - Annual - Waverley Pharma Inc.
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
09/10/26 CA$0.0100 0.00% 2,000
08/10/26 CA$0.0100 0.00% 2,000
  1. Stock Market
  2. Stocks
  3. WAVE Stock